Bristol-myers Squibb Compnay

Syngene International Limited

Kumaravel Selvakumar

Jun Li

James R Corte

Yan Shi

Hao Zhang

Pratik Devasthale

Tianan Fang

Guohua Zhao

Peter Tai Wah Cheng

Jun Shi

Lawrence J Kennedy

Shiwei Tao

Robert F Kaltenbach, Iii

Manoranjan Panda

John F Kadow

Kap-Sun Yeung

Michael Frederick Parker

Xiang-Yang Ye

Deqiang Niu

T G Murali Dhar

John V Duncia

Robert J Cherney

Daniel S Gardner

Upender Velaparthi

Mark D Wittman

Ramesh Kumar Sistla

Bradley C Pearce

Peiying Liu

Bireshwar Dasgupta

Lawrence R Marcin

Xiaojun Han

Rita Civiello

Boris M Seletsky

Chetan Padmakar Darne

Suresh Dhanusu

Steven J Walker

Sutjano Jusuf

Ramesh Babu Reddigunta

Rajesh Onkardas Bora

Swanee E Jacutin-Porte

Susan Nicole Pieniazek

Palanikumar Balasubramanian

Samayamunthula Venkata Satya Arun Kumar Gupta

Chandrasekhar Reddy Rachamreddy

Nagalakshmi Pulicharla

Dibakar Mullick

Leatte R Guernon

Fang Moore

Srinivasan Thangathirupathy

Julio Hernan Cuervo

Xiao Zhu

Jalathi Surendran Nair

Sakthi Kumaran Janakiraman

Mallikarjuna Rao Mettu

Prakash Anjanappa

Subba Reddy Bandreddy

Alyssa H Antropow

Shilpa Maheshwarappa Holehatti

Arul Mozhi Subbiah Karuppiah

Jalathi S Nair

Guobin Miao

Zhengdong Zhu

Paul E Gormisky

Audrey Graham Ross

Ooha Morampudi

Piyush Agarwal

Krishna Mahadevu

Tirupathi Rao Alajangi

Mallikarjun Reddy Sura

Vijaya Kumar Cm

Ramesh Badu Reddigunta

Robert F Iii Kaltenbach

Erika MV Araujo

wherein and X-Xand R-R, along with other variables are as defined herein. The disclosure generally relates to substituted heterocyclic compounds of Formula (Ia), which are inhibitors of PAD4, method for preparing these compounds, pharmaceutical compositions comprising these compounds and use of these compounds in the treatment of a disease or a disorder associated with PAD4 enzyme activity.

Heterocyclic PAD4 inhibitors

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to α-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of α-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

3-substituted propionic acids as αV integrin inhibitors

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to &#x3b1;v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of &#x3b1;-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as &#x3b1;V integrin inhibitors

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists

The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. 

Benzofuran derivatives for the treatment of hepatitis C

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to &#x3b1;v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of av-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions. 

Cyclobutane- and azetidine-containing mono and spirocyclic compounds as &#x3b1;V integrin inhibitors

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to &#x3b1;-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ay-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions. 

3-substituted propionic acids as &#x3b1;V integrin inhibitors

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. 

Compounds for the treatment of hepatitis C

Growing community of inventors

Bengaluru, India

Kumaravel Selvakumar